A common point mutation in the factor-V gene at the exact site (Arg 506) where activated protein C (APC) normally cleaves and inactivates the Va pro-coagulant accounts for APC resistance and is the most important genetic risk factor for venous thrombosis. It has also been suggested as a possible risk factor for stroke. We determined the prevalence of the Arg 506 Gln mutation in 180 patients (mean age 65.3 years) with cerebrovascular disease (138 stroke and 42 TIA) and compared it with that in 70 age-matched controls (mean age 64.9 years). The mutation was no more common in patients than controls [15/180 (8.3%) vs. 5/70 (7.1 %), p = 0,6]. Within the patient group there was no relationship between the presence of the mutation and age of stroke or the occurrence of TIA or stroke. There was no association between the mutation and any particular stroke subtype (large-vessel, lacunar, cardioembolic or unknown). The factor-V Arg 506 Gln mutation is not an important risk factor for stroke and TIA in an unselected group of patients, and routine screening is not justified.

Keywords:
Cerebrovascular disorders, Blood coagulation, Thrombosis, Genetics
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.